--- title: "Lifeward (LFWD) news: convertible notes" url: "https://aibio.space/companies/lifeward/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "LFWD convertible notes news: Lifeward amends senior secured convertible notes tied to Oramed. Lifeward Ltd. (NASDAQ: LFWD), United States." --- LFWD Lifeward Ltd. NASDAQ · United States # Lifeward (LFWD) news LFWD convertible notes news Company Updates · 2026-10-27 ## [Lifeward names Ronen Tsimerman chief financial officer](https://aibio.space/news/lifeward-names-ronen-tsimerman-chief-financial-officer/) The board appointed Ronen Tsimerman as chief financial officer, effective November 1, 2026. His employment agreement is subject to shareholder approval of a renewed compensation policy. ## Latest Lifeward news 1. 2026-09-08 Company Updates [Lifeward investor deck lays out pipeline, reimbursement and Oramed platform](https://aibio.space/news/lifeward-investor-deck-lays-out-pipeline-reimbursement-oramed-platform/) A September 2026 investor presentation filed as Exhibit 99.1 sets out the company's product timeline, its Oramed-linked oral delivery program and its reported cash and revenue. 2. 2026-08-31 Company Updates [Lifeward chief executive Mark Grant departs, Josh Hexter named interim](https://aibio.space/news/lifeward-chief-executive-mark-grant-departs-josh-hexter-named-interim/) Mark Grant leaves as president, chief executive and director effective August 31, 2026, and Josh Hexter becomes interim chief executive on September 1. Rami Aviram is named chief financial officer effective November 1, 2026. 3. 2026-08-14 Company Updates [Lifeward reports second quarter 2026 revenue up 16% to $6.6 million](https://aibio.space/news/lifeward-reports-second-quarter-2026-revenue-up-16-percent-6-6-million/) Lifeward reported a net loss of $11.5 million for the quarter and said a July 6, 2026 financing could provide up to $11.2 million in growth capital. 4. 2026-06-30 Debt Financing [Lifeward amends senior secured convertible notes tied to Oramed](https://aibio.space/news/lifeward-amends-senior-secured-convertible-notes-tied-oramed/) The notes carry 8.0% interest and a $5.40 conversion price. The second tranche depends on ReWalk sales growth or a share price of $13.80 or higher. ## Lifeward at a glance - **Ticker**: LFWD - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $9.4 million ### Related companies - [ProPhase Labs](https://aibio.space/companies/prophase-labs/) OTC: PRPH - [Odyssey Health](https://aibio.space/companies/odyssey-health/) OTC: ODYY - [FAMILY OFFICE OF AMERICA, INC.](https://aibio.space/companies/family-office-of-america/) OTC: FOFA - [Virax Biolabs Group](https://aibio.space/companies/virax-biolabs/) NASDAQ: VRAX - [SkinHealth Systems](https://aibio.space/companies/skinhealth-systems/) NASDAQ: SKIN - [Avantor](https://aibio.space/companies/avantor/) NYSE: AVTR - [Personalis](https://aibio.space/companies/personalis/) NASDAQ: PSNL - [BIOFORCE NANOSCIENCES HOLDINGS, INC.](https://aibio.space/companies/bioforce-nanosciences/) OTC: BFNH ### Also on NASDAQ - [OKYO Pharma](https://aibio.space/companies/okyo-pharma/) OKYO - [TREACE MEDICAL CONCEPTS, INC.](https://aibio.space/companies/treace-medical-concepts/) TMCI - [MANNATECH INC](https://aibio.space/companies/mannatech/) MTEX - [Harrow](https://aibio.space/companies/harrow/) HROW - [Cue Biopharma](https://aibio.space/companies/cue-biopharma/) CUE - [Sunshine Biopharma](https://aibio.space/companies/sunshine-biopharma/) SBFM ## Lifeward annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$22.0 million](https://www.sec.gov/Archives/edgar/data/1607962/000117891326001208/) | [$25.7 million](https://www.sec.gov/Archives/edgar/data/1607962/000117891326001208/) | | Research and development | [$3.2 million](https://www.sec.gov/Archives/edgar/data/1607962/000117891326001208/) | [$4.6 million](https://www.sec.gov/Archives/edgar/data/1607962/000117891326001208/) | | Net income (loss) | [-$19.9 million](https://www.sec.gov/Archives/edgar/data/1607962/000117891326001208/) | [-$28.9 million](https://www.sec.gov/Archives/edgar/data/1607962/000117891326001208/) | | Cash from operations | [-$16.8 million](https://www.sec.gov/Archives/edgar/data/1607962/000117891326001208/) | [-$21.7 million](https://www.sec.gov/Archives/edgar/data/1607962/000117891326001208/) | | Cash and equivalents | [$2.2 million](https://www.sec.gov/Archives/edgar/data/1607962/000117891326004143/) | [$6.7 million](https://www.sec.gov/Archives/edgar/data/1607962/000117891326001208/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $9.4 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Lifeward Has Lifeward sold convertible notes? Our latest story on this, dated Jun 30, 2026: "Lifeward amends senior secured convertible notes tied to Oramed". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/lifeward-amends-senior-secured-convertible-notes-tied-oramed/). What is the ticker symbol of Lifeward? Lifeward Ltd. trades under the ticker LFWD on NASDAQ. Where is Lifeward listed? Lifeward Ltd. is listed on NASDAQ. Which country or territory is Lifeward listed under? Our directory records Lifeward Ltd. under United States. Does aibio.space cover Lifeward? aibio.space lists Lifeward Ltd. among 2,820 public biotech companies and publishes its news here as stories appear. What was Lifeward's revenue last year? $22.0 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Lifeward profitable? Lifeward Ltd. reported a net loss of $19.9 million for the fiscal year ended Dec 31, 2025, and used $16.8 million of cash in operations, per its annual report to the SEC. How much does Lifeward spend on research and development? $3.2 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Lifeward have? $9.4 million in cash at Jun 30, 2026, per its 10-Q. What is the latest Lifeward (LFWD) stock news? Our latest story on Lifeward, dated Oct 27, 2026: "Lifeward names Ronen Tsimerman chief financial officer". The board appointed Ronen Tsimerman as chief financial officer, effective November 1, 2026. His employment agreement is subject to shareholder approval of a renewed compensation policy. [Source](https://aibio.space/news/lifeward-names-ronen-tsimerman-chief-financial-officer/). How can I follow Lifeward (LFWD) news? Press Follow on this page to add Lifeward to your Following list, or subscribe to the aibio.space newsletter. We have published 5 stories naming Lifeward so far, in Company Updates, Debt Financing. ## Investor discussion: Lifeward Members talk about Lifeward (LFWD). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Lifeward, newest first. Each line links the filing it comes from. 1. 2026-05-15 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1607962/000117891326002730/zk2635348.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:LFWD on TradingView](https://www.tradingview.com/symbols/NASDAQ-LFWD/). ## Listing details Lifeward Ltd. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker LFWD, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Lifeward Ltd. - **Ticker**: LFWD - **Listing**: NASDAQ - **Country or territory**: United States Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/lifeward/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Lifeward (LFWD) news: convertible notes", 2026-10-31, https://aibio.space/companies/lifeward/